Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.
Advertisement

Related Content

As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray
Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets
MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
Ranbaxy Reports Higher Than Expected Loss; India Earnings Roundup
Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment

Topics

Advertisement
UsernamePublicRestriction

Register

PS068715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel